Plus   Neg

Stock Alert: Enlivex Therapeutics Tanks 22%

Shares of Enlivex Therapeutics Ltd. (ENLV) tanked over 22% on Monday morning despite no stock-related news.

ENLV is currently trading at $8.86, down $2.64 or 22.96%, on the Nasdaq.

Enlivex Therapeutics, a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing.

Last week, the company announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application covering methods of using Allocetra, the company's immunotherapy product candidate.

The new patent will provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases comprising gout, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.

The company expects that this new patent will be issued in the United States in the coming months.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. recalled about 15,800 units of Off-Road and Utility Vehicles in North America for possible crash hazard, according to a statement issued by the U.S. Consumer Product Safety Commission. There were also an additional 711 units sold in Canada. AstraZeneca's efforts to supply Covid-19 vaccine doses from its Italian unit to Australia has been blocked by the European Union and the Italian Government, citing Australia being non-vulnerable region and delays in domestic supply, among others. Italy's proposal to deny AstraZeneca's request for authorization to export COVID-19 vaccines was subsequently approved by the European Commission. Chipotle Mexican Grill, Inc. is teaming with e.l.f. Cosmetics to launch a limited edition beauty collection on March 10, aiming to support plant-based lifestyles and responsibly-sourced products. The e.l.f. x Chipotle makeup collection will comprise cruelty-free and vegan products inspired by Chipotle's responsibly-raised food.
Follow RTT